Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

3.

Penetration of meropenem in plasma and abdominal tissues from patients undergoing intraabdominal surgery.

Condon RE, Walker AP, Hanna CB, Greenberg RN, Broom A, Pitkin D.

Clin Infect Dis. 1997 Feb;24 Suppl 2:S181-3.

PMID:
9126691
4.

Tissue penetration of Meropenem in patients undergoing gynecologic surgery.

Gall S, Hemsell DL, McGregor JA, Martens MG, Pitkin D, Allen S.

Clin Infect Dis. 1997 Feb;24 Suppl 2:S178-80.

PMID:
9126690
5.

A compilation of meropenem tissue distribution data.

Hutchison M, Faulkner KL, Turner PJ, Haworth SJ, Sheikh W, Nadler H, Pitkin DH.

J Antimicrob Chemother. 1995 Jul;36 Suppl A:43-56.

PMID:
8543498
6.

Comparison of the activity of meropenem with that of other agents in the treatment of intraabdominal, obstetric/gynecologic, and skin and soft tissue.

Pitkin D, Sheikh W, Wilson S, Hemsell D, Nichols R, Nadler H, Dowzicky M.

Clin Infect Dis. 1995 Jun;20 Suppl 2:S372-5.

PMID:
7548602
7.

Are all carbapenems created equal?

Iaconis JP, Nadler HL, Pitkin DH, Sheikh W.

J Antimicrob Chemother. 1994 Sep;34(3):443-4. No abstract available.

PMID:
7530243
8.
9.

Quality control criteria for testing the susceptibility of anaerobic bacteria to meropenem.

Zabransky RJ, Bayola-Mueller L, Jenkins SG, Pitkin DR, Schreckenberger PC, Celig DM, Spiegel CA.

J Clin Microbiol. 1990 Dec;28(12):2804-5.

10.
11.

The postantibiotic effect of meropenem and imipenem on selected bacteria.

Nadler HL, Pitkin DH, Sheikh W.

J Antimicrob Chemother. 1989 Sep;24 Suppl A:225-31.

PMID:
2509416
12.

Kibdelins, novel glycopeptide antibiotics. I. Discovery, production, and biological evaluation.

Shearer MC, Giovenella AJ, Grappel SF, Hedde RD, Mehta RJ, Oh YK, Pan CH, Pitkin DH, Nisbet LJ.

J Antibiot (Tokyo). 1986 Oct;39(10):1386-94.

13.

Charge and lipophilicity govern the pharmacokinetics of glycopeptide antibiotics.

Pitkin DH, Mico BA, Sitrin RD, Nisbet LJ.

Antimicrob Agents Chemother. 1986 Mar;29(3):440-4.

14.
15.

Antimicrobial activity of aridicins, novel glycopeptide antibiotics with high and prolonged levels in blood.

Grappel SF, Giovenella AJ, Phillips L, Pitkin DH, Nisbet LJ.

Antimicrob Agents Chemother. 1985 Nov;28(5):660-2.

16.

Penetration of cefonicid into human breast milk and various body fluids and tissues.

Lou MA, Wu YH, Jacob LS, Pitkin DH.

Rev Infect Dis. 1984 Nov-Dec;6 Suppl 4:S816-20.

PMID:
6522923
17.

Antimicrobial activity of SK&F 88070, an expanded-spectrum cephalosporin with high and prolonged levels in blood.

Grappel SF, Phillips L, Dunn GL, Jakas DR, Pitkin D, Actor P.

Antimicrob Agents Chemother. 1984 Jun;25(6):694-700.

18.

Five cephalosporins: pharmacokinetics and their relation to antibacterial potency.

Sohn C, Pitkin D, Grappel S, Zajac I, Actor P, Alexander F, Lentnek A, Wikler M, Stote R, Dubb J.

Clin Ther. 1984;6(4):560-70.

PMID:
6467282
19.

Ceftizoxime kinetics and renal handling.

Dubb J, Actor P, Pitkin D, Alexander F, Familiar R, Ehrlich S, Stote R.

Clin Pharmacol Ther. 1982 Apr;31(4):516-21.

PMID:
6277546
20.

Kinetics and renal handling of cefonicid.

Pitkin D, Dubb J, Actor P, Alexander F, Ehrlich S, Familiar R, Stote R.

Clin Pharmacol Ther. 1981 Nov;30(5):587-93.

PMID:
7297018
21.
22.

In vitro and in vivo laboratory studies on three hydroxyiminophenylacetyl cephalosporins with particular reference to SK&F 80303, an unusually long-acting cephalosporin.

Uri JV, Actor P, Zajac I, Pitkin DH, Phillips L, Guarini JR, Bartus HF, Polansky TJ, Dunn GL, Hoover JR, Weisbach JA.

J Antibiot (Tokyo). 1979 Nov;32(11):1161-7.

23.

SK&F 75073, new parenteral broad-spectrum cephalosporin with high and prolonged serum levels.

Actor P, Uri JV, Zajac I, Guarini JR, Phillips L, Pitkin DH, Berges DA, Dunn GL, Hoover JR, Weisbach JA.

Antimicrob Agents Chemother. 1978 May;13(5):784-90.

24.

Semiautomated turbidimetric microbiological assay for cefazaflur.

Pitkin DH, Actor P, Baldinus JG, Post A, Weisbach JA.

J Antibiot (Tokyo). 1978 Apr;31(4):359-62.

25.

Biological and chemotherapeutic studies on three semisynthetic cephamycins.

Uri JV, Actor P, Guarini JR, Phillips L, Pitkin D, Demarinis RM, Weisbach JA.

J Antibiot (Tokyo). 1978 Jan;31(1):82-91.

26.

Comparative stability of cephalothin and cefazolin in buffer or human serum.

Pitkin D, Actor P, Filan JJ, White R, Weisbach JA.

Antimicrob Agents Chemother. 1977 Aug;12(2):284-5.

27.

Distribution of sodium cefazolin in serum, muscle, bone marrow, and bone of normal rabbits.

Pitkin DH, Sachs C, Zajac I, Actor P.

Antimicrob Agents Chemother. 1977 Apr;11(4):760-2.

29.

Automated spectrophotometric assay of cefazolin.

Holl WW, O'Brien M, Filan J, Mazeika TR, Post A, Pitkin D, Actor P.

J Pharm Sci. 1975 Jul;64(7):1232-4.

PMID:
1151690
30.

Semiautomated turbidimetric microbiological assay for determination of cefazolin.

Pitkin D, Actor P, Holl W, Post A, Weisbach JA.

Antimicrob Agents Chemother. 1974 Mar;5(3):223-7.

31.
33.
34.

The in vivo interaction of Candida albicans and Salmonella typhimurium.

Ramirez C, Ransom JP, Pitkin DH.

Microbiol Esp. 1968 Jan-Jun;21(1):89-91. No abstract available.

PMID:
4888327
35.

Effect of endotoxin on the delayed hypersensitivity reaction.

Pitkin DH.

Proc Soc Exp Biol Med. 1967 Feb;124(2):651-3. No abstract available.

PMID:
5335653
36.

Effect of physiological stress on the delayed hypersensitivity reaction.

Pitkin DH.

Proc Soc Exp Biol Med. 1965 Nov;120(2):350-1. No abstract available.

PMID:
5856412
37.

THE POSSIBLE SIGNIFICANCE OF LACTIC ACID LEVELS IN NORMAL AND ABNORMAL BOVINE MILK SAMPLES.

PITKIN DH, MORSE GE.

Am J Vet Res. 1964 Nov;25:1658-62. No abstract available.

PMID:
14227166
38.

An albumin-like protein in "mastitic" milk. I. Physical, chemical, and immunologic identification.

SHAH PC, MORSE GE, PITKIN DH.

Am J Vet Res. 1963 Jul;24:723-9. No abstract available.

PMID:
13988354

Supplemental Content

Loading ...
Support Center